The FDA has approved Pyzchiva® (ustekinumab-ttwe), a biosimilar antagonist of human interleukin (IL)-12 and IL-23, for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, set to be launched in the US market by February 2025.
The U.S. Food and Drug Administration issued draft guidance for drugmakers and medical device makers to improve diversity in clinical trials, emphasizing the importance of actions to support more equitable access to medical innovations.
Judge rules in favor of AHA, declaring HHS's online tracking restrictions unlawful, impacting hospitals' use of web technologies for health information sharing.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
Judge rules in favor of AHA, declaring HHS's online tracking restrictions unlawful, impacting hospitals' use of web technologies for health information sharing.
A new combination therapy for treating colorectal cancer has been approved by the FDA, offering potential new hope for patients with a specific gene mutation.
The Congressional Budget Office projects a rise in the uninsured rate to 8.9% by 2034, driven by immigration and policy changes affecting young adults, despite a record low of 7.2% in 2023.
The U.S. Preventive Services Task Force recommends intensive behavioral interventions for children and adolescents with high BMI to manage weight and improve health.